Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
about
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisCurrent status of alloimmunity.Tumor Regression and Allograft Rejection after Administration of Anti-PD-1Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Challenges faced when identifying patients for combination immunotherapy.Management of High-Risk Squamous Cell Carcinoma of the Skin.Ipilimumab in melanoma.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.Immune checkpoint inhibitors in challenging populations.Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology.Renal complications of immune checkpoint blockade.Skin Cancers in Organ Transplant Recipients.Treatment options for metastatic melanoma in solid organ transplant recipients.Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockadeIpilimumab in patients with melanoma and autoimmune diseasePembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation.Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
P2860
Q26785746-CBF59F32-0526-47EE-A470-1A757C1E44E8Q34047345-E77A4548-2425-4F98-9E90-5800C56FF816Q36850761-31189B7D-5E9F-4C12-B9FD-6658E75F55A6Q37346073-C638314F-7C03-4744-AB52-1ED8518A322FQ37346118-9810ADB4-ECC2-4A74-8E58-4DF2E2D7AD5FQ38261202-B696240A-486B-422C-92D9-4E291C07DCC1Q38586991-C2F8A510-CF87-418E-88DB-FE8EB7DA9ABDQ38638046-9F1814F0-633F-4BEC-89A0-A680C7C9272CQ38855017-00281CE6-8C13-44C6-BA98-353FAA8A6E2CQ38893697-0DF159DA-63A4-46C0-9D6E-CD7812339CF0Q38918124-EBD71E3D-F0DD-443B-A601-CEB5B23E8EE3Q38930084-10907D66-827B-44FE-9DA8-E2B3897EB8EBQ38939708-FE496D87-1B77-4A50-91A2-10B36C99EE03Q39009781-1F2AA3BC-FEDE-47FF-852F-EFD7124A4330Q39018620-9A92EC3C-9F20-47F5-8498-5F42E827EFBEQ39131602-C0DA8B2B-C618-4A88-ABF1-1C1B9B0E06DBQ39337780-ECF54437-E91A-4AFE-A14D-B8B9C64B7535Q39564822-BF8C6960-E942-4E2A-BB3E-C7AB59525FDBQ40148698-600407E4-E006-41B8-98DC-1436C5B7D93DQ41299313-685E76C4-12AB-43FF-B423-8AE1AD500FB7Q41991133-5DF3F5EF-3527-4C1A-97BD-4A493EA9D330Q42315438-0B4F902E-2065-4D7E-9FBA-059D0D50589DQ42429273-77FDB86F-7BA7-4F41-9810-1DE4E0ABE600Q47148480-1B711EAB-5F1B-454A-83A7-559F06BE7897Q56893675-9A33295B-B763-4623-9F12-16130FD021D6Q59135661-AE579849-E856-479E-A873-5682D6707F26
P2860
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Successful administration of i ...... ents with metastatic melanoma.
@en
type
label
Successful administration of i ...... ents with metastatic melanoma.
@en
prefLabel
Successful administration of i ...... ents with metastatic melanoma.
@en
P2093
P2860
P356
P1476
Successful administration of i ...... ents with metastatic melanoma.
@en
P2093
Edward S Kraus
Evan J Lipson
Mabel A Bodell
William H Sharfman
P2860
P304
P356
10.1200/JCO.2013.49.2314
P407
P577
2014-02-03T00:00:00Z